Regulation
FDA clears Sequel Med Tech’s twiist system for type 2 diabetes
The FDA has cleared Sequel Med Tech's twiist AID system for adults aged 18 and older with insulin-treated type 2 diabetes. The clearance expands the automated insulin delivery platform's authorized use from type 1 diabetes, marking a significant regulatory milestone for the vendor's diabetes management portfolio.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network